European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.

An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.

Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.

The MOVe-OUT study will continue to the phase 3 portion and evaluate 800 mg of the therapy administered twice daily.

Those taking methotrexate had lower seroconversion rates compared to controls.

While infection risk is not eliminated, the vaccine still provided significant protection.

The second wave in South Africa was larger and saw the Beta lineage dominate.

Investigators followed patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) for 6 months to review their outcomes.

A Swiss population-based study showed more people in socioeconomically challenged places tested positive more frequently, saw higher hospitalizations, and greater mortality rates than those in higher socioeconomic places.

Azithromycin versus standard care in patients with mild-to-moderate COVID-19, did not reduce the risk of hospital admission or mortality.

A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.

Oral ibrexafungerp could cut hospital stays for patients with invasive candidiasis infections.

It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.

Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.

The data were released as part of the now-cancelled European Congress of Clinical Microbiology and Infectious Diseases.

Previous research has suggested an association between bacteria from the Bovis group streptococci, Clostridium septicum and colorectal cancer

Investigators have hypothesized that scarlet fever transmission is driven by pediatric cases with symptomatic disease.

A new survey found that parents in Spain were the most supportive of vaccinations when compared with their counterparts in 4 other European countries.

Whole genome sequencing revealed little overlap between MDROs found in pets and pet owners.

Elizabeth Hirsch, PharmD, and Elizabeth Smith, PharmD candidate, discuss fosfomycin susceptibility testing.

Minh-Hong Nguyen, MD, discusses rezafungin as a potential treatment option for intra-abdominal candidiasis.

Steven Tong, PhD, discusses the benefit of investigator-initiated studies.

László Majoros, MD, PhD, discusses how nearly all invasive fungal infections are being treated with echinocandins.

Tristan Ferry, MD, PhD, discusses bacteriophage therapy as an alternative treatment for certain patients.

Marin Kollef, MD, discusses what makes the 3-gram dose regimen of ceftolozane/tazobactam unique.

Steven Tong, PhD, discusses the next steps for research on combination therapy for MRSA bacteremia.

Experts from the fields of microbiology and infectious disease share their biggest takeaways and highlights from ECCMID 2019.